Jason Cohen, Editor

About the Author Jason Cohen, Editor


Top Analyst Boosts Price Target for Aldeyra Therapeutics Inc (ALDX); Here’s Why

Ritu Baral sees 35% upside for Aldeyra on back of positive Phase 2a dry eye study.

Read more

Top Analyst Shines Light on Intercept Pharmaceuticals Inc’s (ICPT) Dear Health Care Provider Letter

Dear doctor: My shares just fell 15%.

Read more

Analysts Punish Otonomy Inc (OTIC) in Wake of Meniere’s Disease Drug Failure

Wednesday turned out to be a nightmare for Otonomy Inc (NASDAQ:OTIC) investors, after the drug …

Read more

Juno Therapeutics Inc (JUNO) Looks Well Positioned in Light of KITE Takeout: Top Analyst

David Nierengarten Re-evaluates JUNO; Upgrades Shares to Outperform

Read more

Chardan Bullish on The Medicines Company (MDCO); Reiterates $85 Price Target

In a research report issued Wednesday, Chardan analyst Gbola Amusa reiterated a Buy rating on …

Read more

Oppenheimer Comments on The Medicines Company (MDCO) Following FDA Approval for VABOMERE

The Medicines Company’s Vabomere – A Solid Option for CarbapenemResistant cUTIs: Oppenheimer

Read more

Paratek Pharmaceuticals Inc (PRTK) Lined Up for Potential Takeover, Ultragenyx Pharmaceutical Inc (RARE) Has Better Value Drivers Than Failed Ace-ER Program

A Peek Into Today’s Volatile Biotech Stocks

Read more

Ultragenyx Pharmaceutical Inc (RARE) Tumbles on Ace-ER Failure; Top Analyst Remains Bullish

Cowen Sees Light at the End of the Tunnel for Ultragenyx Following a Failed Phase 3 Study in GNEM

Read more

Cantor Bets on Opko Health Inc. (OPK); Sees 240% Upside

Looking for a reason to buy shares of Opko Health Inc. (NASDAQ:OPK)? How about three …

Read more

Cantor Shines Light on TherapeuticsMD Inc (TXMD) Following Publication of Clinical Data in Menopause

Cantor analyst William Tanner is out today with a few insights on TherapeuticsMD Inc (NYSEMKT:TXMD), after the …

Read more